Normunity
Normunity raises $75M Series B at $500M valuation
Quick Facts
Normunity: Series B Funding Round
Normunity has successfully raised $75M in Series B funding, reaching a valuation of $500M.
Company Overview
T cell engager therapies
Funding Details
The Series B round was led by Samsara BioCapital, with participation from Enavate Sciences, Regeneron Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2020
- Employees: 80+
- Category: HealthTech
Investment
Normunity plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Samsara BioCapital: Verified investor in Series B
- Enavate Sciences: Verified investor in Series B
- Regeneron Ventures: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
